News

Alkermes Boosts Acquisition Proposal for Avadel Pharmaceuticals

Alkermes Boosts Acquisition Proposal for Avadel Pharmaceuticals

Strategic Move by Alkermes to Acquire Avadel Pharmaceuticals

Alkermes plc (NASDAQ: ALKS) is making headlines with its increased proposal to acquire Avadel Pharmaceuticals plc (NASDAQ: AVDL). The revised offer, which highlights Alkermes' commitment to enriching shareholder value, involves a total transaction consideration of up to $22.50 per share. This includes $21.00 in cash and a non-transferable contingent value right (CVR) worth an additional potential $1.50 per share, contingent on the U.S. Food and Drug Administration's LUMRYZ™ approval for treating idiopathic hypersomnia in adults by 2028.

Details of the Increased Offer

The acquisition, which has been approved by the boards of both companies, values Avadel at around $2.37 billion. Alkermes is optimistic that the deal will close in the first quarter of 2026, subject to satisfaction of specific conditions including the amended terms set out in the recent revised offer announcement.

Context of the Acquisition

The journey to this increased offer began when Avadel received an unsolicited proposal from Lundbeck A/S. Following an evaluation of this competing offer, Avadel determined that Alkermes' proposal, particularly the terms regarding the CVR, presented a superior option for its shareholders. This decision showcases Avadel's strategic approach to maximizing value for its stakeholders.

Implications of the Amended Agreement

To facilitate this acquisition, Alkermes and Avadel established an amendment to their definitive transaction agreement. This amendment includes an extended timeframe for the transaction, emphasizing Alkermes' dedication to meeting regulatory requirements swiftly and effectively. Investment financing for the acquisition has already been secured, reinforcing Alkermes’ readiness to see this deal through.

Financial Advisors and Legal Counsel

J.P. Morgan is advising Alkermes exclusively for this transaction, while financial counsel for Avadel includes Morgan Stanley and Goldman Sachs. This collaboration between financial leaders ensures both companies navigate the complex landscape of mergers and acquisitions successfully.

About Alkermes plc

Alkermes is a global biopharmaceutical powerhouse, focused on developing innovative treatments in neuroscience and incorporating proprietary products for various conditions such as alcohol and opioid dependence, schizophrenia, and bipolar disorder. With a robust pipeline aimed at addressing neurological disorders, Alkermes' acquisition of Avadel represents a significant step toward expanding its product offerings and market reach.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals is dedicated to transforming existing medications to improve patient outcomes. With its lead product, LUMRYZ™, approved for narcolepsy, Avadel stands at the forefront of innovation in biopharmaceutical development. This proposed acquisition by Alkermes further affirms Avadel's potential in the industry.

The Future of the Acquisition

As part of the acquisition process, shareholders of Avadel are encouraged to stay informed about the developments leading up to the definitive proxy statement that will detail the next steps for the transaction. This ongoing communication will be vital in ensuring shareholder interests are prioritized throughout the acquisition process.

Next Steps for Shareholders

Shareholders are advised to review all communications from both companies, particularly concerning the potential impacts of the acquisition on their stock. Avadel will provide detailed instructions on how to exercise shareholder rights during the scheme meeting considerations.

Frequently Asked Questions

What is the increased offer from Alkermes for Avadel?

The revised offer includes a total consideration of up to $22.50 per share, comprising $21 in cash and a potential $1.50 contingent value right.

When is the expected closing date of the acquisition?

The transaction is expected to close in the first quarter of 2026, pending the satisfaction of certain conditions.

Who are the financial advisors for the acquisition?

J.P. Morgan is acting exclusively for Alkermes, while Morgan Stanley and Goldman Sachs are advising Avadel.

What should shareholders do in response to the acquisition proposal?

Shareholders should stay engaged with communications from both companies and consider their voting options as details are provided in the upcoming proxy statements.

How does this acquisition benefit Alkermes and Avadel?

This acquisition aims to enhance the value of both companies by combining resources and expanding product offerings, particularly in the neuroscience therapeutic area.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 48

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 117

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 56

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 79

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 382

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 59

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 87

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading

Top 5 Most Recently Viewed Articles

Choice Hotels Unveils Comprehensive Sustainability Efforts

Updated Category News Views 387

Choice Hotels International Launches 2024 Sustainability Report Choice Hotels International, Inc. (NYSE: CHH), a leading global lodging franchisor, has officially released its 2024 Sustainability Report, showcasing its ongoing commitment to environmental sustainability. The report highlights the company's innovative approaches to reducing its carbon footprint and...

Continue Reading
Revitalizing Communities Through Skilled Trades Initiatives

Updated Category News Views 157

Revitalizing Communities Through Skilled Trades Initiatives In an important moment for many towns across America that are striving for renewal, a new initiative has emerged to shine a light on the necessity of skilled trades. The campaign, titled Careers in Manufacturing, is aimed at highlighting how vital these trades are for both local economies and the workforce on the...

Continue Reading
Color Me Mine Celebrates Growth and Franchise Success

Updated Category News Views 344

Color Me Mine Achieves Remarkable Mid-Year Growth Color Me Mine, a leading paint-your-own pottery franchise, is excited to announce significant growth through its studio expansion and franchisee success. The brand is witnessing a thriving landscape of opportunities, fueled by enthusiastic franchise owners who are making their mark in various communities. Studio Expansion...

Continue Reading
Earnings Insights: Companies Set to Report Soon

Updated Category News Views 202

Upcoming Earnings Reports for Major Companies As the earnings season approaches, investors and analysts eagerly anticipate the financial results from several prominent companies. This article highlights some of the key players expected to announce their quarterly results. Companies Reporting Before the Market Opens UP Fintech Holding (TIGR) UP Fintech Holding is projected...

Continue Reading
Cogent Biosciences Shares Insights at Prestigious Healthcare Event

Updated Category News Views 207

Cogent Biosciences Highlights Participation in Major Healthcare Conference Cogent Biosciences, Inc. (Nasdaq: COGT), a pioneering biotechnology company, is ready to showcase its innovative approach to precision medicine at the highly regarded J.P. Morgan Healthcare Conference. Taking place in San Francisco, this annual event is a crucial platform for industry leaders to...

Continue Reading